|
Apr 8
|
Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society
|
|
Apr 2
|
Why Alkermes (ALKS) is Poised to Beat Earnings Estimates Again
|
|
Mar 29
|
Investors in Alkermes (NASDAQ:ALKS) have seen favorable returns of 44% over the past three years
|
|
Mar 25
|
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
|
|
Mar 25
|
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
|
|
Mar 20
|
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
|
|
Mar 18
|
Insider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)
|
|
Mar 15
|
Alkermes (ALKS) Stock Moves -0.45%: What You Should Know
|
|
Mar 13
|
3 Reasons Why Alkermes (ALKS) Is a Great Growth Stock
|
|
Mar 12
|
Here's Why Alkermes (ALKS) is a Strong Momentum Stock
|
|
Mar 8
|
Here's Why Alkermes (ALKS) is a Strong Growth Stock
|
|
Mar 7
|
Why Alkermes (ALKS) Outpaced the Stock Market Today
|
|
Mar 7
|
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
|
|
Feb 8
|
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024
|
|
Feb 8
|
Alkermes (ALKS) to Report Q4 Results: Wall Street Expects Earnings Growth
|
|
Feb 7
|
Alkermes (ALKS) Stock Falls Amid Market Uptick: What Investors Need to Know
|
|
Jan 12
|
Alkermes (ALKS) Outpaces Stock Market Gains: What You Should Know
|
|
Jan 5
|
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
|
|
Jan 3
|
Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Jan 3
|
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan)
|